Asia-Pacific Point-of-Care Diagnostics Market (2025-2032)

The Asia-Pacific Point-of-Care Diagnostics Market is projected to reach $11.80 billion by 2032, at a CAGR of 7.5% from 2025 to 2032.

Published
Jan 2025
Pages
200
Format
PDF + Excel
Report ID
MRHC - 104988
Base year
2024
Market size · USD billion · 2024–2032Forecast 2025–2032 · 7.5% CAGR
2032 · FORECAST
$11.80B
2032
$11.80B
CAGR 2025–2032
7.5%
$15B$11.25B$7.5B$3.75B0
2024
2025
'26
'27
'28
'29
'30
'31
'32

2024 baseline · 2025–2032 forecast at 7.5% CAGR · hover a bar for the value

Key highlights

01

In 2025, the Consumables Segment is Expected to Dominate the Asia-Pacific Point-of-Care Diagnostics Market

02

In 2025, the Blood Sample Segment is Expected to Dominate the Asia-Pacific Point-of-Care Diagnostics Market

03

In 2025, the Blood Glucose Monitoring Segment is Expected to Dominate the Asia-Pacific Point-of-Care Diagnostics Market

04

In 2025, the Lateral Flow Assays Segment is Expected to Dominate the Asia-Pacific Point-of-Care Diagnostics Market

05

In 2025, the Hospitals Segment is Expected to Dominate the Asia-Pacific Point-of-Care Diagnostics Market

06

China: Fastest-growing Country-level Market

Report summary

ParticularsDetails
Base Year2024
Estimated Year2025
Forecast Period2025–2032
Market Size (2032)USD 11.80 billion
CAGR (2025–2032)7.5%
FormatPDF, Excel & Cloud Portal · 200 pages
Segments CoveredBy Offering: Consumables, Instruments, Software and Services · By Platform: Lateral Flow Assays, Molecular Diagnostics, Other Platforms · By Application: Blood Glucose Monitoring, Infectious Disease Testing Parasitic Infections Testing, Blood-Borne Infections Testing Hepatitis, HIV, Other Blood-Borne Infections, Influenza, Pneumonia, Tuberculosis (TB), Salmonellosis, E. Coli Infections, Pregnancy Testing, Fertility Testing, Prothrombin Time (PT/INR) Testing, Activated Clotting Time (ACT/APTT) Testing · By Sample Type: Blood Sample, Nasopharyngeal Swab, Urine Sample, Saliva Sample, Other Sample Types · By End User: Hospitals, Home Care/Self-Testing, Physician Offices & Ambulatory Care Settings, Diagnostics Laboratories, Other End Users · By Sample
Countries CoveredAsia-Pacific (RoAPAC)
Key CompaniesAbbott Laboratories (U.S.), Siemens Healthineers AG, QuidelOrtho Corporation (U.S.), F. Hoffmann-La Roche Ltd, Danaher Corporation (U.S.), Becton, Dickinson and Company (U.S.), Trinity Biotech plc, Werfen, Nova Biomedical (U.S.), Sekisui Diagnostics, LLC. (U.S.), Thermo Fisher Scientific Inc. (U.S.)

Report overview

Scope note

Segments covered: offering, platform, application, sample type, end user, sample. Regions: Asia-Pacific.

Point-of-Care diagnostics (PoC diagnostics), also known as bedside or near-patient testing, refers to medical diagnostic testing conducted near the patient, typically at the location where healthcare is provided. The key characteristic of PoC diagnostics is the ability to deliver rapid results, often within minutes, allowing healthcare providers to make immediate treatment decisions or recommendations based on the test outcomes.

The growth of this market is driven by the increasing prevalence of chronic diseases, innovations in PoC tests, and a lack of skilled technicians for performing lab tests. However, the pricing pressure due to fluctuations in reimbursements restrains the market’s growth. Furthermore, healthcare professionals’ increasing preference for PoC tests over lab tests will offer significant market growth opportunities. However, a lack of awareness regarding the use of PoC devices challenges the market’s growth.

The demand for pathology services has grown significantly in recent years and is expected to grow further during the forecast period. However, the pathology workforce has not increased in line with this demand. Delays in initial diagnosis can lead to delays in treatment. The workforce shortage can be attributed to aging and retiring professionals and the lack of adequate histology programs to train enough new entrants.

According to Medical Futurist, by 2032, the number of active pathologists may drop by 30% compared to 2010 levels. The Chinese Pathologist Association states that there are only 20,000 licensed pathologists in China, a country with a population of over 1.4 billion. Furthermore, there is a growing need for clinical laboratory workers due to their acute shortage. Factors such as laboratory professionals retiring or leaving the profession, the increasing demand for laboratory services, and changes in clinical laboratory science practices due to technological advances contribute to this shortage of skilled professionals. This shortage disrupts the delivery of healthcare services, impacting patients and healthcare providers. Thus, the shortage of skilled professionals leads to delays in diagnosis and treatment, leading to an increased reliance on self-testing. These factors are boosting the adoption of PoC diagnostics, driving the growth of this market.

Many healthcare professionals in hospitals and clinical laboratories prefer using point-of-care diagnostics to diagnose various health conditions promptly. Healthcare professionals are replacing established diagnostic methods (microscopy, pathogen culturing, biochemical testing, conventional polymerase chain reaction (PCR), enzyme-linked immunoassay (ELISA), and other time-consuming diagnostic methods) with new point-of-care diagnostic techniques that provide higher levels of efficiency and reproducibility. As point-of-care diagnostics have superior utility, experts are changing their traditional approaches. This acceptance of point-of-care diagnostics is supporting the research & development efforts of clinical laboratories and other health-services companies in the diagnostics industry. This inclination towards point-of-care methods and practices among physicians drives the growth of the point-of-care diagnostics market.

Report infographic

Asia-Pacific Point-of-Care Diagnostics Market
Asia-Pacific Point-of-Care Diagnostics Market · Report infographic

Table of contents

13 chapters · 115 sections · 200 pages · click to expand
Review the full research scope before you buy. Chapters can also be purchased individually.

1.1Market Definition & Scope
1.2Market Ecosystem
1.3Currency & Limitations
1.4Key Stakeholders

Segmental analysis

SegmentLargest share (2025)Fastest growth (2025–2032)
By OfferingConsumables—
By Sample TypeBlood Sample—
By ApplicationBlood Glucose Monitoring—
By PlatformLateral Flow Assays—
By End UserHospitals—
01

By Offering

  • The consumables segment is expected to account for the largest share of the Asia-Pacific Point-of-Care Diagnostics Market.
  • Factors such as the increasing number of immunoassay and molecular diagnostics tests being performed globally, leading to recurrent purchases of kits and reagents, rise in product approvals, and technological advancements in PoC testing are contributing to the large share of this market.
CoversConsumablesInstrumentsSoftware and Services
02

By Sample Type

  • The blood sample segment is expected to account for the largest share of the Asia-Pacific Point-of-Care Diagnostics Market.
  • The large market share of this segment is attributed to the availability of a large variety of tests using blood samples, increasing prevalence of various chronic diseases, and increasing consumer awareness regarding the monitoring of chronic diseases.
CoversBlood SampleNasopharyngeal SwabUrine SampleSaliva SampleOther Sample Types
03

By Application

  • The blood glucose monitoring segment is expected to account for the largest share of the Asia-Pacific Point-of-Care Diagnostics Market.
  • The large market share of this segment is attributed to the rising prevalence of diabetes and the growing need for blood glucose monitoring.
  • For instance, according to the International Diabetes Federation (IDF), in Southeast Asia, the number of adults with diabetes is estimated to reach 113 million by 2032 from 90 million in 2021.
CoversBlood Glucose MonitoringInfectious Disease Testing Parasitic Infections TestingBlood-Borne Infections Testing HepatitisHIVOther Blood-Borne InfectionsInfluenzaPneumoniaTuberculosis (TB)SalmonellosisE. Coli InfectionsPregnancy TestingFertility TestingProthrombin Time (PT/INR) TestingActivated Clotting Time (ACT/APTT) Testing
04

By Platform

  • The lateral flow assays segment is expected to account for the largest share of the Asia-Pacific Point-of-Care Diagnostics Market.
  • Lateral flow assays are simple one-step assays that are low-cost devices.
  • The major factors contributing to this segment's largest share are the growing prevalence of chronic and infectious diseases, technological innovations, and the advantages of lateral flow assays, such as cost-effectiveness and rapid results.
CoversLateral Flow AssaysMolecular DiagnosticsOther Platforms
05

By End User

  • The hospitals segment is expected to account for the largest share of the Asia-Pacific Point-of-Care Diagnostics Market.
  • The rising number of hospitals and clinics, increasing demand for point-of-care diagnostics, and increasing healthcare expenditure worldwide are driving the demand for PoC diagnostics.
  • Furthermore, the outbreak of the COVID-19 pandemic has resulted in an increased demand for PoC diagnostic kits in hospitals & clinics for the treatment and prevention of COVID-19 infections.
CoversHospitalsHome Care/Self-TestingPhysician Offices & Ambulatory Care SettingsDiagnostics LaboratoriesOther End Users

Geographic analysis

01

Asia-Pacific

Fastest growth
RoAPAC

The rising prevalence of infectious & chronic diseases, the growing aging population, and the increasing adoption of self-testing mainly drive the growth of this market. Healthcare spending in China has shown year-on-year growth. According to The World Bank Group, the health expenditure (% of GDP) increased from 4.94% in 2015 to 5.59% in 2020. China: Fastest-growing Country-level Market

Competitive landscape

Companies profiled (12)
  • Abbott Laboratories (U.S.)
  • Siemens Healthineers AG · Germany
  • QuidelOrtho Corporation (U.S.)
  • F. Hoffmann-La Roche Ltd · Switzerland
  • Danaher Corporation (U.S.)
  • Becton
  • Dickinson and Company (U.S.)
  • Trinity Biotech plc · Ireland
  • Werfen · Spain
  • Nova Biomedical (U.S.)
  • Sekisui Diagnostics, LLC. (U.S.)
  • Thermo Fisher Scientific Inc. (U.S.)

Frequently asked questions

The Asia-Pacific Point-of-Care market study covers the market sizes & forecasts for types of point-of-care tests used in hospitals, home care/self-testing, physician offices & ambulatory care settings, diagnostics laboratories. The report includes the value analysis of various segments of the Asia-Pacific Point-of-Care at the country/region level.

Cite this report

Meticulous Research. (2025). Asia-Pacific Point-of-Care Diagnostics Market - Opportunity Analysis And Industry Forecast (2025-2032) (Report No. MRHC - 104988). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/asia-pacific-point-of-care-diagnostics-market-5671

Search Market Intelligence

Search across reports, blogs, press releases, and industries